Member Info for Bermudashorts

Bunsie -

We disagree and that's perfectly OK but we now have the ridiculous situation whereby inanaco posts on advfn, you copy and paste to lse, someone replies on lse to your copy and paste and inanaco copy and pastes that reply onto advfn and then replies. It doesn't work and is very difficult to follow the flow of the thread. (IMO)

As for the ban, I agree, it has prevented him from posting good information here but banned he is. Why would anyone have you banned? I certainly won't be reporting you and hope nobody else does either.

Chelsea,

Yes, I know there have been issues and some dreadful posts on advfn (and on here too!) and with you in mind, I thought long and hard about posting earlier. I know it would be difficult for you to post there but honestly, there are some good posters who post interesting views and useful research and if you can face it at some stage, it might be worth having a go at just reading the useful posts and filtering everything else.

Bunsie,

Why the need for the dig? I don't have to do without his investigative skills. I've been enjoying his posts and discussing SCLP related issues with him on advfn. I simply don't think it works when you have the board clogged with these long posts taken out of context. It's an opinion I'm perfectly entitled to hold and to voice. The reason for his ban is irrelevant and my logic isn't flawed. A poster is either banned or they're not and re-posting an occasional post is one thing but allowing blanket posting makes a mockery of the decision to ban him. I genuinely believe that lse should allow him back and remove the need for you to act as his voice box.

OK going to wade into the debate here.

I have been guilty of re-posting some of Inanaco's stuff from ADVFN here and I think that the odd post is fine when it's something really significant. However, this blanket re-posting doesn't work at all IMO. If you want to read these long 'science' posts then register on advfn and join the debate or simply lurk in the background. If you don't like the posting style of some posters over there, then there's always the filter button.

I also find it slightly odd that lse admin go to the lengths of banning a poster only to allow his posts to be re-posted in volume. Admin, if you're reading, you might as well let Inanaco back - would solve the whole problem!

This may already have been posted but the clinical trials record for MRx0518 was updated yesterday to show that a new study centre has opened for recruitment - the Houston Methodist Cancer Center.

https://clinicaltrials.gov/ct2/show/NCT03637803?term=4d+pharma&draw=2&rank=5

https://www.dailymail.co.uk/sciencetech/article-9137823/Bacteria-GUT-affects-Covid-19-severity.html

Another excellent presentation from Andrew Newland yesterday and worth re-posting the link for any new to Angle who may be looking in.

https://www.youtube.com/watch?v=dmihuELlhDM

Interesting review from Bloomberg today with their vaccine tracker. First part is purely related to the US but worth scrolling down a bit to the global section. The two interactive charts at the bottom are really interesting. Look at India but also the lack of provision in many poorer countries.

https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

Chelsea- intriguing in the sense that we haven't a clue what it covers - it's such a general title. If you go back and look at most of the other patents from Scancell, the titles are reasonably specific and give a good indication of what platform they belong to. With this one, it's anyone's guess.

Konar - thanks

Konar,

No and a while to wait to find out - any ideas?

A new patent application from Scancell was listed in the UK Patent Office's Journal today. Title of the application doesn't give much away - 'Immunotherapy' and it was lodged on 23rd November. Intriguing.

https://www.ipo.gov.uk/p-pj?startYear=2020&startMonth=December&startDay=30th+-+6867&endYear=2021&endMonth=January&endDay=6th+-+6868&filter=scancell&perPage=10&sort=Publication+Date

Good grief, +10.6%

nomoneyman,

Excellent thanks for posting

Ruck,

I'm sure Inanaco will correct me if I'm wrong, but I don't think LD is saying they're building a new version of SN14 vaccine. I think she's saying they're building a SA 501.v2 preclinical model (presumably in mice?) to test that SN14 is also effective against the South African variant. If it is then great. If it isn't, then as Scancell have often highlighted, one of the advantages of the ImmunoBody platform is the ability to 'plug and play'. They can adapt as necessary.

I just emailed Scancell reply

They are building the Virus SA variant 501.v2 to test SN14

Great news

DG

Correct, the vaccination rate so far hasn't been catastrophically slow at all - it's been constrained by supplies of the vaccine, the storage requirements and the need to monitor each patient for 15 minutes after vaccination. As they get supplies, they are administering them. Worth repeating that we have the 3rd highest vaccination rate in the world and it's about to ramp up significantly as supplies of the AZN vaccine come along.

The UK has now secured supplies of over 350 million doses of a variety of vaccines but of course only 2 have received MHRA approval so far, BioNTech with an order of 40m doses and AZN with 100m. Ordering these vaccines is essentially booking your place on the waiting list for manufactured supplies. As the vaccines are manufactured they're being shipped out and I'm sure that all manufacturers are working flat out to increase production . Having said that, I was reading yesterday that there may be a potential issue with global supply of the lipid nanoparticles used to carry the mRNA vaccines so good job Scancell haven't gone down that road.

One other quick point, it was mentioned yesterday that the J&J vaccine should be the next to report results and submit for approval. The good news is that vaccine was also selected by the UK's vaccine taskforce and they have secured 30m doses.

Ray/AB124

Yes approval of the AZN vaccine could be a game changer and as gooosed has pointed out over on advfn, the J&J vaccine which is a single dose should be coming along shortly too.

As I understand it, at the moment, there aren't huge stockpiles of any vaccines sitting in UK fridges and freezers waiting to be administered. In fact I believe the issue is getting hold of enough of the Pfizer vaccine rather than lack of staff to administer it. This all changes when production of the AZN vax is ramped up and that's when we'll need this army of volunteers to be ready to go. Next week sees the first few hospitals dosing with the AZN vax - let's hope it goes well with no unforeseen problems.

We shouldn't overlook the fact that thanks to a huge effort from the MHRA and NHS staff, the UK has now vaccinated just under 1 million people and has the 3rd highest vaccination rate in the World with only Israel and Bahrain in front. As ever, it's easy to knock and miss opportunities to acknowledge achievements and give credit where credit is due.

AB124

I should probably have made it clear that my comments were mainly aimed at the section of the article covering the delayed second dose.

However, I did also find Sir John Bell's point that the NHS routinely administer 20 to 30 million flu vaccines every year in October and November encouraging in terms of their ability to deliver the various Covid vaccines. That equates to between 2.5 and 3.75 million people per week and I don't believe we have that level of covid vaccines available anyway at the moment. Hopefully the bureaucracy facing potential volunteers will be scaled back and the nonsense removed, leaving only the essential items in time for the ramping up stage where additional help may be needed.

Bill,

Yes thanks very much for the link to the interview with Sir John Bell. What a contrast between his calm, reassuring and logical approach and the outrage of the Daily Mail article. Worth listening to the interview before reading the articles in hasiba's link.

Time to shut down the laptop - wishing you all a very happy Christmas.